Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc. as indicated in the metadata) on August 18, 2021. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance:
- Stock Price Deficiency: The average closing price of the Company's common stock over the 30 trading days prior to August 17, 2021, fell below $1.00 per share.
- Listing Requirement: Nasdaq Listing Rule 5450(a)(1) requires a minimum average closing price of $1.00 per share.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq indicating a failure to satisfy the Minimum Bid Requirement. This notice has no immediate effect on the listing or trading of the common stock but initiates a compliance period.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days (until February 14, 2022) to regain compliance. This requires the closing bid price to be at least $1.00 per share for a minimum of ten consecutive business days.
- Secondary Compliance Period: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period, contingent on meeting other listing standards (e.g., market value of publicly held shares).
- Risks: There is no assurance the Company will regain compliance. Failure to do so could result in delisting. The Company retains the right to appeal a delisting determination to a Hearings Panel.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of Salarius Pharmaceuticals (SLRX) to assess proximity to the $1.00 threshold.
- Monitor subsequent filings for updates on the 180-day compliance status.
- Review the company's market capitalization and public float to determine eligibility for a second compliance period if needed.
- Check for any corporate actions (e.g., reverse stock splits) that might be proposed to address the bid price deficiency.